High-grade astrocytoma in very young children

Robert P. Sanders, Mehmet Kocak, Peter C. Burger, Thomas E. Merchant, Amar Gajjar, Alberto Broniscer

Research output: Contribution to journalArticle

Abstract

Background. High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients. Procedure. We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005. Results. Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3% (SE 12.2%), and 5-year event-free survival (EFS) was 28.6% (SE 12.1%). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction. Conclusions. Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe.

Original languageEnglish (US)
Pages (from-to)888-893
Number of pages6
JournalPediatric Blood and Cancer
Volume49
Issue number7
DOIs
StatePublished - Dec 2007

Fingerprint

Astrocytoma
Survival
Survivors
Disease-Free Survival
Histology
Aptitude
Glioblastoma
Proportional Hazards Models
Glioma
Disease Progression
Neoplasms
Biopsy
Recurrence
Drug Therapy

Keywords

  • Brain tumors
  • Late effects of cancer treatment
  • Neuro-oncology
  • Neurotoxicity of therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Sanders, R. P., Kocak, M., Burger, P. C., Merchant, T. E., Gajjar, A., & Broniscer, A. (2007). High-grade astrocytoma in very young children. Pediatric Blood and Cancer, 49(7), 888-893. https://doi.org/10.1002/pbc.21272

High-grade astrocytoma in very young children. / Sanders, Robert P.; Kocak, Mehmet; Burger, Peter C.; Merchant, Thomas E.; Gajjar, Amar; Broniscer, Alberto.

In: Pediatric Blood and Cancer, Vol. 49, No. 7, 12.2007, p. 888-893.

Research output: Contribution to journalArticle

Sanders, RP, Kocak, M, Burger, PC, Merchant, TE, Gajjar, A & Broniscer, A 2007, 'High-grade astrocytoma in very young children', Pediatric Blood and Cancer, vol. 49, no. 7, pp. 888-893. https://doi.org/10.1002/pbc.21272
Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, Broniscer A. High-grade astrocytoma in very young children. Pediatric Blood and Cancer. 2007 Dec;49(7):888-893. https://doi.org/10.1002/pbc.21272
Sanders, Robert P. ; Kocak, Mehmet ; Burger, Peter C. ; Merchant, Thomas E. ; Gajjar, Amar ; Broniscer, Alberto. / High-grade astrocytoma in very young children. In: Pediatric Blood and Cancer. 2007 ; Vol. 49, No. 7. pp. 888-893.
@article{8a8444dcfee14ed1999e20d59bbf237d,
title = "High-grade astrocytoma in very young children",
abstract = "Background. High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients. Procedure. We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005. Results. Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3{\%} (SE 12.2{\%}), and 5-year event-free survival (EFS) was 28.6{\%} (SE 12.1{\%}). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95{\%}CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction. Conclusions. Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe.",
keywords = "Brain tumors, Late effects of cancer treatment, Neuro-oncology, Neurotoxicity of therapy",
author = "Sanders, {Robert P.} and Mehmet Kocak and Burger, {Peter C.} and Merchant, {Thomas E.} and Amar Gajjar and Alberto Broniscer",
year = "2007",
month = "12",
doi = "10.1002/pbc.21272",
language = "English (US)",
volume = "49",
pages = "888--893",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - High-grade astrocytoma in very young children

AU - Sanders, Robert P.

AU - Kocak, Mehmet

AU - Burger, Peter C.

AU - Merchant, Thomas E.

AU - Gajjar, Amar

AU - Broniscer, Alberto

PY - 2007/12

Y1 - 2007/12

N2 - Background. High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients. Procedure. We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005. Results. Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3% (SE 12.2%), and 5-year event-free survival (EFS) was 28.6% (SE 12.1%). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction. Conclusions. Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe.

AB - Background. High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients. Procedure. We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005. Results. Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3% (SE 12.2%), and 5-year event-free survival (EFS) was 28.6% (SE 12.1%). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction. Conclusions. Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe.

KW - Brain tumors

KW - Late effects of cancer treatment

KW - Neuro-oncology

KW - Neurotoxicity of therapy

UR - http://www.scopus.com/inward/record.url?scp=35648934426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648934426&partnerID=8YFLogxK

U2 - 10.1002/pbc.21272

DO - 10.1002/pbc.21272

M3 - Article

VL - 49

SP - 888

EP - 893

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -